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Edwin M. Horwitz, Mary M. Horowitz, Nancy L. DiFronzo, Donald B. Kohn,
Helen E. Heslop, for the BMT CTN State of the Science Cell and Gene Therapy CommitteeMany innovative cell therapies that directly relate
to hematopoietic stem cell transplantation are at an
early stage of development, and until recently, most
were not ready to progress to later phase multicenter
studies. However, as the field has matured, it is likely
that some strategies will be ready to test in later phase
studies and pathways will need to be established for un-
dertaking such trials.
The Blood andMarrow Transplant Clinical Trials
Network (BMT CTN) anticipates being able to pro-
vide infrastructural support for a limited number of
such studies when the goal of the novel cell therapy
is to improve the outcome of transplant by reconstitut-
ing antitumor or antiinfectious immunity or modulat-
ing alloreactivity or to use transplant as a means of
genetic correction for inherited diseases. This brief
report is intended to assist investigators by outlining
the process by which such studies can be submitted,
and reviewed and implemented by the BMT CTN.
The BMT CTN was established in 2001 by the
National Heart, Lung, and Blood Institute (NHLBI)
and the National Cancer Institute (NCI) as an infra-
structure to conduct multiinstitutional Phase II and
Phase III trials focused on improving outcomes in
blood and marrow transplantation (BMT). The BMT
CTN is a network of 16 Core Transplant Centers/
Consortia,more than 60AffiliatedTransplantCenters,
and a Data Coordinating Center (DCC). Its activities
are overseen by a Steering Committee composed of
representatives from the Core and Affiliate Centers,
the DCC, NHLBI, and NCI (www.bmtctn.net).Division of Oncology/Blood and Marrow Transplanta-
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6/j.bbmt.2010.08.020Many prominent advances in clinical oncology have
resulted from cooperative group trials, underscoring
the importance of collaborative clinical trials to the
medical community. The BMT CTN is conducting
more than 20 Phase II and Phase III trials to address is-
sues critical to BMT patients. Although the results of
most of these trials are still forthcoming, these studies
have the potential to change practice and establish
a new standard of care. Eleven BMT CTN trials have
completed enrollment; patient follow-up continues on
5 of these, with data analysis in progress or recently
completed for the others. Accrual continues on 11 trials
with 4 additional trials expected to open in 2010.
Although the BMT CTN considers issues relevant to
both autologous and allogeneic BMT, it has a major
focus on allogeneic transplantation. Of the 400 to 600
patients enrolled on BMT CTN trials annually, more
than 80% are allogeneic transplant recipients. The
BMT CTN infrastructure may be used to conduct
multiinstitutional Phase II studies that would either es-
tablish the efficacy of novel cell therapies to a level that
would justify a large Phase III trial. For rare diseases or
indications, licensure may be possible with a smaller
study—for example, European investigators have re-
ceived orphan drug designation from the European
Medicines Agency for gene transfer to hemopoietic
stem cells to treat ADA deficiency based on studies
with small numbers of patients. Study requirements for
specific indications should be discussed with the FDA.
A number of steps need to be followed for a cell therapy
phase II/III trial to be supported by the BMT CTN.PRIOR TO CONCEPT SUBMISSION
TOTHE BMT CTN
Phase I Clinical Trial Data
Themost important single element in the develop-
ment of a Phase II trial proposal is the acquisition of
appropriate Phase I data to support the safety of the
cell product and its therapeutic application, as well as
to provide at least preliminary evidence of activity suf-
ficient to warrant the investment of time and resources
required for larger multiinstitutional studies.
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however, greater clinical risk or greater financial bur-
den will mandate more substantial Phase I data. In
general, the Phase I data should include a minimum
of 15 patients in an adult study or 12 patients in pedi-
atrics, with an acceptable safety profile for the cell
therapy product although a smaller number may suf-
fice for orphan diseases if response rates are high
and endpoints for safety are met. Because the re-
sources required to initiate and complete a multicenter
Phase II study are considerable, it is important that
investigators be confident that they have identified
the precise product with which they will proceed.
Complex biologic therapies such as cell therapies re-
quire multiple parameters to be optimized, such as
the type of target cell, manufacturing processes, and
choice of vector. It may be necessary to perform iter-
ative Phase I studies or review the results of multiple
Phase I studies from different centers to ensure that
an optimal product is chosen before proceeding to
later phase studies. It is also advantageous if the inves-
tigators develop and conduct ancillary laboratory
studies, for example by using validated biomarkers of
efficacy (Figure 1).Figure 1. PresuRegulatory Considerations
It is recommended that the Phase I study sponsor
hold a End-of-Phase 1 (EOP1) conference with the
FDA review team to document that the Agency does
not identify anymajor barriers to proceeding to a Phase
II trial based on the available Phase I data. The concept
for the proposed Phase II study should be discussed at
that time to allow the Agency an opportunity to advise
whether a new investigational new drug (IND) will be
needed, or whether the current IND can be amended.
It may be appropriate to submit a clinical development
plan for FDA review. Although the resources of the
BMT CTN are substantial, they are not unlimited
and so the leadership of the BMT CTN and the
NHLBI/NCI will only be able to accept the most
promising studies. Hence, FDA approval does not
guarantee that the BMT CTN will decide to under-
take a particular trial.Product Preparation and Distribution
In most cases, cell therapy trials will involve pro-
cessing human cells in the laboratory. Many trials in-
clude genetic modification of cells by viral or nonviralbmission.
Table 1. Implementation of Phase II Cell Therapy Trial in the
BMT CTN
Area Tasks
Production Develop budget
Decide whether central versus distributed production
Submit a proposal to PACT if central production
Develop and validate SOPs
Validate shipping if required
Regulatory Define needed reviews
Decide on IND sponsor
Develop MOU to assign responsibilities
Establish sequence and timeline of required reviews
Review of clinical protocol by the NHLBI PRC and DSMB
Write and submit RAC submission if needed
Write Investigator’s brochure
Write and submit IND to the FDA
Select Sites
IRB (and IBC if needed) review at sites
Operational Map protocol and develop SOPs
Develop case report forms
Develop database
Finalize correlative studies
SOP indicates standard operating procedures; NHLBI, National Heart,
Lung, and Blood Institute; FDA, U.S. Food and Drug Administration;
IND, Investigational New Drug; IRB, Institutional Review Board; IBC, In-
stitutional Biosafety Committee; DSMB, Data and Safety Monitoring
Board; PSC, Planing Steering Committee; BMT CT, Blood and Marrow
Transplant Clinical Trials Network.
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processes is necessary for Phase I trials, many new
manufacturing challenges exist when amulticenter trial
is planned. Hence, investigators are strongly encour-
aged to consider using the Production Assistance for
Cellular Therapies (PACT), an NHLBI-supported
cell processing program (http://www.pactgroup.net/
index2.htm). This program provides a central manu-
facturing site for trials and can assist with technical
aspects of manufacturing, such as scale-up, standard
operating procedure (SOP) development, assay devel-
opment, and phenotype determination, as well as qual-
ity assurance and quality control. Once an application
is accepted by PACT, all agreed upon services are pro-
vided free of charge to the investigators. If the study
involves gene transfer, the NHLBI Gene Therapy
Resource Program (GTRP) is a resource for providing
clinical grade lentiviral and AAV vectors (http://
www.gtrp.org/). For other vectors, investigators must
identify and secure funding for manufacture by an aca-
demic center (see http://www.aabmonline.org/for a
listing) or a commercial supplier.
Operational Issues
Most operational issues will be addressed during
the protocol development process after a proposal is
accepted by the BMT CTN. However, proposals
should discuss any potential problems, the expense of
replication competent retrovirus (RCR) testing if
a product is genetically modified with retroviral vec-
tors or the need for long-term follow-up needed for
subjects receiving integrating vectors.
Issues that should be addressed prior to submission
are outlined in Table 1.SUBMISSION AND REVIEW
Submission of Proposal
Investigators interested in exploring the feasibility
of conducting a novel cell therapy trial in the BMT
CTN should submit a proposal to the BMT CTN
DCC. The template for BMT CTN proposals is sim-
ple and can be obtained by contacting the BMT CTN
DCC at bmtctn@emmes.com. For all trials, investiga-
tors must provide the following elements:
1. Hypothesis
2. Specific aims
3. Background
4. Eligibility criteria
5. Treatment plan
6. Primary outcome
7. Secondary outcomes
8. Basic study design
9. Timeline
10. Funding sourcesIn cell therapy studies investigators should also in-
clude a discussion of regulatory issues, the EOP1 min-
utes if available, and preliminary plans for product
manufacture and distribution.
Proposal Review
Proposals are reviewed by the BMT CTN Exec-
utive Committee which meets monthly by conference
call. Proposals considered consistent with the BMT
CTN’s mission and not conflicting with ongoing
studies are then referred to the full Steering
Committee during its in-person meetings, which
occur thrice yearly, usually in February, July, and Oc-
tober. Investigators are invited to present their pro-
posals to the Committee, but this is not required.
Proposals are approved and prioritized based on sci-
entific merit, feasibility, expected participation of
Network centers, and funding availability. Cell ther-
apy trials will be evaluated by a group of experts in
the field charged with providing their recommenda-
tions to the Steering Committee. The investigator
submitting the concept should expect that review
will be an iterative process, in which they receive
input on study design and logistics as the protocol
is refined. If the proposal is selected to move forward,
a protocol writing committee will be formed that will
include the investigator submitting the concept,
members from the steering committee and participat-
ing centers, the DCC, and individuals with particular
expertise in the target disease or application. For
a cell therapy application, there would be representa-
tion from PACT or the manufacturing centers
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tors. This group would write the protocol, reporting
to the steering committee and receiving feedback
during the process. The protocol writing committee
will simultaneously work with the DCC to consider
implementation issues. The review process is summa-
rized in Figure 2.IMPLEMENTATION
Regulatory
Cell therapy trials will, in most cases, require an
IND Application approval from the FDA. The re-
search teammust determine who (individual or institu-
tion) will assume responsibility as the sponsor and hold
the IND. Additionally, an individual must be desig-
nated as the Principal Investigator and accept the cor-
responding responsibilities. A detailed description ofFigure 2. Review of conthe responsibilities of the sponsor and site investiga-
tors for a multiinstitution trial can be obtained on
the FDA Website (http://www.accessdata.fda.gov/
scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart5
312&showFR51&subpartNode521:5.0.1.1.3.4). Al-
though extramural funding for cell therapy trials is
available, most agencies, including the NIH and the
BMTCTN,might decide not to act as a study sponsor.
One of the FDA requirements for cell therapy
studies is submission of a detailed data and safety mon-
itoring plan. The DCC for the BMT CTN can take
responsibility for some of these functions, such as
audits and maintenance of regulatory approvals. Addi-
tionally, all BMT CTN studies are monitored by an
NHLBI-appointed Data and Safety Monitoring
Board. If neither the NIH nor BMT CTN elects to
serve as study sponsor, a memorandum of understand-
ing must be developed between the BMT CTN and
the sponsor delineating the BMT CTN’s scope ofcept by BMT CTN.
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the data and safety monitoring plan submitted to the
FDA. The exact division of responsibilities does not
have to be worked out in advance but investigators
are encouraged to discuss this issue with the BMT
CTN leadership and to propose a tentative plan in
their proposals.
For multicenter studies the FDA will also require
the sponsor to develop an Investigator’s Brochure
that should be reviewed annually, and updated as
needed. Instructions for preparing an Investigator’s
Brochure can be found on the FDA Website (http://
www.fdaregulatory.com/ichgcp/brochure.html). The
DCC can assist with this activity for some trials.
Each participating institution will be required to
obtain approval for the protocol from their local insti-
tutional review board (IRB). This task can be labor in-
tensive for many investigators so institutions should be
selected, in part, based on their capacity to enroll
sufficient numbers of patients to justify seeking IRB
approval. Nomination of participating centers should
be a part of the proposal and should be discussed
with the DCC in advance. The latter can provide
data on center-specific transplant activity to assist in
these determinations. In some cases, the DCC can
facilitate surveys of centers to determine whether
they have the necessary capabilities (in addition to an
adequate patient population) to participate in specific
protocols. If the proposed study utilizes a gene transfer
protocol, then the Recombinant DNA Advisory
Committee of the Office of Biotechnology Activities
and each local Institutional Biosafety Committee
(IBC) must approve the final protocol. The time and
sequence for these approvals must be considered in
estimating a time line for the study in the proposal
and experience of centers in obtaining IBC approval
should also be considered in center selection.
Production
In making final decisions on cell production, the
research team must determine if the cell product is
best produced locally by each participating institu-
tions, or centrally by a single laboratory, which then
distributes the product to the participating institu-
tions. Local production will limit participation to in-
stitutions that maintain appropriate manufacturing
facilities and will require SOPs to ensure product
consistency and quality at multiple production sites.
Evidence that distributed production of a quality prod-
uct is feasible must be provided. If the product is to beproduced centrally, the site of productionmust be con-
sidered. The production facility must devise SOPs for
distribution and validate these protocols, focusing on
the integrity of the cell product after it arrives at the
treating institution. A budget will be developed and
funding considerations may influence decisions recen-
tralized or distributed production. As the cost of
manufacture and testing for cell products is high,
particularly those that are genetically modified and
require additional testing, it may be necessary to seek
additional funding, or consider utilizing resource
programs available through NIH for clinical grade
cellular products (PACT) and vectors (GTRP).Operational Issues
Many operational issues will be study-specific.
Investigators will need to map all protocol processes
and develop SOPs. Case report forms previously de-
veloped by the BMT CTN will be available for some
study endpoints but study-specific forms will also be
required. Investigators will also need to decide if
correlative studies should be performed locally or cen-
trally and either validate comparability of assays or
shipping conditions. PACT can assist with shipping
and/or assay validation.SUMMARY
The BMT CTN infrastructure can facilitate trials
for innovative multiinstitutional Phase II trials of cell
therapy relevant to BMT. However, there are several
key considerations for these Phase II proposals. First,
the research team should have sufficient Phase I data
to justify the resources required for a large multicenter
clinical trial. Second, cell product preparation and dis-
tribution processes should be developed and qualified,
and the various aspects of cell processing assistance
should be determined. If the PACT resource is being
considered, the application procedure for requesting
manufacturing assistance is available on theirWebsite.
Finally, a tentative plan for operation of the study
by the sponsor should be developed prior to submis-
sion of the proposed study to the BMT CTN.
Additional questions regarding the development of
protocols intended for BMT CTN submission can
be directed to bmtctn@emmes.com. Proposals can be
submitted to the BMT CTN electronically to the
same address. All investigators are encouraged to uti-
lize this valuable resource.
